[1] TANG XW, JIA YT, TIAN XJ, et al.Excavation and evaluation of post-marketing safety signals of levofloxacin,moxifloxacin and ciprofloxacin: a study based on adverse drug reactions in the real world[J]. Chinese Journal of New Drugs(中国新药杂志), 2018, 27(5): 596-603. [2] CHANG XY, GUO GM.Literature review of adverse drug reactions of quinolones-induced thrombocytopenia[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(4): 227-230. [3] LUO XX, LIU Y, XUE XC, et al.Literature analysis of 55 cases of quinolone-induced thrombocytopenia[J]. Chinese Journal of Clinical Pharmacy(中国临床药学杂志), 2018, 27(3): 188-191. [4] NAINA HV, HARRIS S.Drug-induced immune thrombocytopenia[J]. N Engl J Med, 2007, 357(18): 1869-1872. [5] KAM T, ALEXANDER M.Drug-induced immune thrombocytopenia[J]. J Pharm Pract, 2014, 27(5): 430-433. [6] XIAO HL.Comparative analysis on update of drug labels of fluoroquinolones in China and the United States[J]. Drug Evaluation Research(药物评价研究), 2016, 36(9): 919-924. [7] NIWA T, SUZUKI A, SAKAKIBARA S, et al.Retrospective cohort chart review study of factors associated with development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy[J]. Clin Ther, 2009, 31(10): 2126-2133. [8] ZHAO J, YANG YR.Literature analysis of antibacterial drug-induced thrombocytopenia[J]. Drugs & Clinic(现代药物与临床), 2017, 32(10): 2025-2031. [9] JIA WP.Re-evaluation of the safety of fluoroquinolones based on automatic monitoring system[D]. Beijing: Chinese People's Liberation Army Medical College, 2018. [10] MUSTAFA M, RAMAZAN BA, MUSTAFA K, et al.Moxifloxacin related thrombocytopeniae: a case report[J]. Tuberkuloz ve Toraks, 2016, 64(3): 250-252. [11] ANDREW WS, ANDY SL,THEODORE E.Levofloxacin-induced acute immune-mediated thrombocytopenia of rapid-onset[J]. J Pharm Prac, 2018, 31(2): 234-237. [12] LI J, FANG YH, LIAO LW, et al.Risk factors for linezolid-associated thrombocytopenia in critically ill adult patients[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2018, 36(9): 743-746. [13] CHEN F, ZHANG C, CUI M.A case of severe thrombocytopenia caused by linezolid injection[J]. Chinese Journal of Pharmaco-vigilance(中国药物警戒), 2017, 14(7): 254-256. [14] LIN YX, WANG HH, FU XF, et al.Analysis of influencing factors for anti-infection efficacy of fluoroquinolones for elderly patients with respiratory tract infection[J]. Medical Review(医学综述), 2015, 21(4): 727-729. [15] WANG MX, REN LM, WANG CP.Pharmacokinetics of new fluoroquinolones in patients with renal impairment[J]. Chinese Pharmaceutical Journal(中国药学杂志), 2000, 35(8) : 562-564. [16] ZHOU CJ.Influence of different dosing schedules on the characteristics of adverse reactions of levofloxacin[J]. Modern Practical Medicine(现代实用医学), 2014, 26(8): 1033-1034. [17] WING WY, KWOK CC.Management of adverse reactions to high-dose moxifloxacin used in multidrug- resistant tuberculosis treatment programmes[J]. Respirology, 2019, 25(6): 201-203. [18] PROVAN D, BAGLIN T, DOKAL I, et al.Oxford handbook of clinical haematology[M]. Oxford: Oxford University Press, 2015: 18. [19] MAILMAN JF, STIGANT C, MARTINUSEN D.Moxifloxacin-induced immune-mediated thrombocytopenia in a chronic kidney disease patient receiving hemodialysis[J]. Ann Pharmacother, 2014, 48(7) : 919-922. |